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Alzheimer’s disease (AD) is a devastating disease characterized by synaptic and neuronal loss in the elderly. Compelling
evidence suggests that soluble amyloid-β peptide (Aβ) oligomers induce synaptic loss in AD. Aβ-induced synaptic
dysfunction is dependent on overstimulation of N-methyl-D-aspartate receptors (NMDARs) resulting in aberrant
activation of redox-mediated events as well as elevation of cytoplasmic Ca2+, which in turn triggers downstream
pathways involving phospho-tau (p-tau), caspases, Cdk5/dynamin-related protein 1 (Drp1), calcineurin/PP2B, PP2A,
Gsk-3β, Fyn, cofilin, and CaMKII and causes endocytosis of AMPA receptors (AMPARs) as well as NMDARs. Dysfunction
in these pathways leads to mitochondrial dysfunction, bioenergetic compromise and consequent synaptic dysfunction
and loss, impaired long-term potentiation (LTP), and cognitive decline. Evidence also suggests that Aβ may, at least in
part, mediate these events by causing an aberrant rise in extrasynaptic glutamate levels by inhibiting glutamate uptake
or triggering glutamate release from glial cells. Consequent extrasynaptic NMDAR (eNMDAR) overstimulation then
results in synaptic dysfunction via the aforementioned pathways. Consistent with this model of Aβ-induced synaptic loss,
Aβ synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine).
PSD-95, an important scaffolding protein that regulates synaptic distribution and activity of both NMDA and AMPA
receptors, is also functionally disrupted by Aβ. PSD-95 dysregulation is likely an important intermediate step in the
pathological cascade of events caused by Aβ. In summary, Aβ-induced synaptic dysfunction is a complicated process
involving multiple pathways, components and biological events, and their underlying mechanisms, albeit as yet
incompletely understood, may offer hope for new therapeutic avenues.
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Alzheimer’s disease (AD) is the most common form of
dementia among the elderly. It is clinically characterized
by progressive memory loss and cognitive dysfunction,
with the eventual inability to perform activities of daily
living (ADLs). According to the Alzheimer’s Association
(http://www.alz.org), 5.4 million Americans are currently
living with Alzheimer’s disease, and one in eight older
Americans will develop AD. While drugs are available to
temporarily improve memory and cognitive function or
delay the progress of dementia, AD remains a devastating
neurodegenerative disorder without any effective cure or
disease-modifying therapy [1,2]. Following diagnosis, AD
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Although AD is pathologically characterized by the
presence of extracellular deposition of plaques com-
prised of Aβ peptide and neurofibrillary tangles (NFTs)
comprised of hyperphosphorylated-tau protein, accu-
mulating evidence suggests that these abnormal protein
deposits are unlikely the causative events in AD as Aβ
plaque or NFT volume poorly correlate with the severity
of dementia. Instead, the degree of dementia in premor-
tem patients correlates more closely with the level of
soluble oligomers of Aβ species in postmortem brains,
especially in hippocampal and cortex regions associated
with learning and memory function [3-5]. Aβ peptides
are proteolytic products of the amyloid precursor pro-
tein (APP) and are sequentially cleaved by β- and γ-
secretases [6]. Although Aβ peptides of varying length
are produced, Aβ1-42 is considered to be comparativelyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oligomers and consequent fibril deposits. Aβ oligomers,
also termed as Aβ-derived diffusible ligands (ADDLs),
are thought to induce synaptic loss and progressive cog-
nitive decline in AD, whereas monomers and fibrillary ag-
gregates may be more inconsequential to pathogenesis [7].
In addition, synaptic protein depletion [8-10] and synaptic
loss [11,12] are also found in the same regions in human
AD or mild cognitive impairment (MCI) postmortem
brains, and the level of synaptic reduction closely parallels
the degree of premortem cognitive impairment. These
studies suggest that oligomeric Aβ elevation and synaptic
loss, rather than Aβ plaque load, may represent the best
indicators of the severity of dementia or cognitive impair-
ment in AD. Moreover, these findings imply that rescue of
synapses could prove to be disease modifying in AD.
Using transgenic animal models of AD, additional stud-
ies suggest that synaptic loss is induced by pathological
Aβ elevation [13]. Although the molecular mechanism is
still not fully understood, it is generally believed that Aβ
oligomers at pathological concentrations trigger (most
likely via an indirect pathway) overstimulation of extrasy-
naptic NMDA receptors (eNMDARs), leading to aberrant
redox events and Ca2+ upregulation. Subsequent activa-
tion of downstream signal transduction pathways trigger a
cascade of pathological events leading to synaptic dis-
ruption and neuronal loss. These include increased oxi-
dative/nitrosative stress and mitochondrial dysfunction
with consequent bioenergetic compromise, leading to dys-
regulation of synaptic neurotransmission and abnormal
neuronal network activity [7,14]. A number of synaptic pro-
teins have been proposed as potential Aβ-binding partners
under pathological conditions and their interactions are be-
lieved to mediate Aβ-induced synaptic dysfunction. These
proteins include, but are not limited to, α7-nicotinic acetyl-
choline receptors (α7nAChRs) [15], NMDARs [16,17],
mGluR5 [18], neurotrophin receptor p75NTR [19], cellular
prion protein (PrPC) [20], PSD-95 [21], glutamate trans-
porter [22], ephrin type-B receptor 2 (EphB2) [23], and
ephrin type-A receptor 4 (EphA4) [24,25]. The involvement
of some of these proteins in Aβ-mediated neurotoxicity will
be discussed in the following sections.
Oligomeric Aβ induces synaptic dysfunction in AD mice
AD or amnestic MCI patients usually have trouble with
spatial orientation in their daily routine and perform poorly
in clinically-designed, hippocampus-dependent memory
and navigation tests [26-28]. Studies using animal models
of AD have suggested that soluble oligomeric Aβ species
are critical in initiating a pathogenic cascade leading to
synaptic dysfunction, neuronal loss, and AD-like cognitive
impairment [7]. The association between amyloidogenic
Aβ species and age-dependent memory loss was first
described in Tg2576 mice expressing a human APP695transgene containing the Swedish mutation (K670N/
M671L) [29]. These mice show elevated brain Aβ1-42/43
levels by ELISA and perform poorly in Morris water maze
tests of spatial memory [29,30]. The association between
Aβ and cognitive impairment has also been documented
in other transgenic (Tg) animal models of AD including
3XTg-AD mice, which express three human mutant AD
gene variants (PS1M146V, APPSwe, and tauP301L) and
develop progressive plaques and tangles [31,32] and the
human amyloid precursor protein-overexpressing (hAPP)
J20 mouse model [33]. Synaptic dysfunction was also ob-
served in these AD transgenic mice with aberrantly ele-
vated levels of oligomeric Aβ and deficits in learning and
memory (see selected reviews: [34-36]). Moreover, these
studies showed that synaptic and cognitive impairments
are associated with the elevation of soluble oligomeric Aβ
species and usually evident prior to the appearance of pla-
ques and tangles in the relevant brain regions.
NMDAR-dependent long-term potentiation (LTP) in
hippocampus has attracted broad attention as an elec-
trophysiological measurement of synaptic strength and
plasticity in various AD models. LTP induction requires
activation of NMDARs, which triggers a signaling cas-
cade that induces the recruitment of AMPARs into the
postsynaptic membrane [37]. On the other hand, NMDAR-
dependent long-term depression (LTD) is an activity-
dependent reduction in the efficacy of neuronal synapses,
which is mediated, at least in part, by AMPAR endocytosis
[37]. Multiple studies have shown that LTP is impaired in
AD or Aβ-exposed wild-type hippocampus, and this im-
pairment is dependent on NMDARs and downstream path-
ways [38-44]. In contrast to LTP, Aβ application enhances
LTD [22,45,46], consistent with the notion that Aβ causes
synaptic depression.
Emerging evidence suggests that Aβ-induced synaptic
dysfunction is dependent on NMDAR-mediated activity
and occurs via aberrant redox events as well as elevation
of cytoplasmic Ca2+ and activation of downstream
pathways involving Ca2+-dependent protein phosphatase
calcineurin/PP2B and protein phosphatase 2A (PP2A)
(Figure 1) [47-49]. Concerning the Ca2+-dependent events,
upon activation, calcineurin further activates or inactivates
its target proteins via dephosphorylation. For example, de-
phosphorylation and activation of the actin filament sever-
ing protein cofilin by calcineurin result in dendritic spine
loss, which can be rescued by overexpression of the in-
active cofilin phosphomimetic S3D [48]. Interestingly, a
recent study reported that Aβ oligomers interact with
murine PirB (paired immunoglobulin-like receptor B) and
its human ortholog LilrB2 (leukocyte immunoglobulin-
like receptor B2) with nanomolar affinity. This interaction
enhanced cofilin signaling and contributed to memory loss
in AD transgenic mice [50]. Aβ-induced synaptic degener-
ation also involves surface removal and endocytosis of
Figure 1 Schematic diagram outlining mechanisms of oligomeric Aβ-induced synaptic dysfunction. At pathological concentrations, Aβ
oligomers may interact with multiple astrocytic, microglial, and neuronal synaptic proteins, including α7-AChRs and NMDARs, triggering a series
of toxic synaptic events. These events include aberrant activation of NMDARs (especially NR2B-containing extrasynaptic NMDARs), elevated
neuronal calcium influx, calcium-dependent activation of calcineurin/PP2B and its downstream signal transduction pathways, involving cofilin,
GSK-3β, CREB, and MEF2. This results in aberrant redox reactions and severing/depolymerizing F-actin, tau-hyperphosphorylation, endocytosis of
AMPARs, and eventually leads to synaptic dysfunction and cognitive impairment.
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downregulated through endocytosis in wild-type neurons
rapidly upon Aβ-application [51] and in AD transgenic
mice [52]. Concurrently, AMPAR-mediated synaptic
currents are also downregulated in AD double knock-in
(mutant APP and PS1) transgenic mice [53]. Aβ-induced
AMPAR endocytosis or surface removal is dependent on
the activation of calcineurin/PP2B [54] and requires
downregulation of Ca2+/calmodulin-dependent protein
kinase II (CaMKII) [55]. Similar to AMPARs, Aβ can in-
duce surface removal or endocytosis of NMDARs, which
is mediated by dephosphorylation of NR2B (GluN2B), an
NMDAR subunit, at p-Tyr1472 by the tyrosine phosphat-
ase STEP [56,57]. Interestingly, the apoptotic effector
component caspase-3 has also been suggested to play a
role in synaptic plasticity and its activation is required in
AMPAR removal and consequent LTD induction [58]. Ac-
tivation of caspase-3 has been further shown to trigger
early synaptic dysfunction in AD transgenic mice [59].
This is consistent with the observation that caspase-3 is
enriched in postsynaptic densities [60]. In addition to ionic
glutamate receptor NMDARs and AMPARs, metabotropicglutamate receptors (mGluRs) at extrasynaptic or perisy-
naptic sites have also been shown to play an important
role in Aβ-induced synaptic dysfunction [46], likely acti-
vated by pathologically elevated glutamate at extrasynaptic
sites [22].
It has also been reported that pathological concentrations
of Aβ oligomers disrupt glutamate uptake, thus increasing
glutamate levels to enhance LTD [22] or impair LTP [61].
Consistent with these results, the levels of both glutamate
transporters EAAT1 and EAAT2, which are responsible for
the majority of glutamate uptake in glial cells, are downreg-
ulated in the hippocampus of AD patients [62]. Due to im-
paired glutamate uptake, glutamate spills out of synapses
and accumulates in the extrasynaptic spaces, thereby indu-
cing overactivation of NR2B-predominant eNMDARs [61].
In addition to attenuated glutamate uptake, oligomeric Aβ
increases glutamate levels by triggering aberrant astrocyte
glutamate release and accumulation within the extrasynap-
tic space thereby overactivating eNMDARs, which results
in synaptic damage via a variety of aberrant transcriptional
cascades and redox-mediated posttranslational modifica-
tions [63-69]. These eNMDAR-mediated pathways include
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and Ca2+-overload of mitochondria, generating exces-
sive reactive nitrogen and oxygen species (RNS/ROS).
This excess results in aberrant oxidation reactions, such
as S-nitrosylation and sulfonation, on various proteins,
thereby disrupting their normal activity. One example is
illustrated by excessive S-nitrosylation or sulfonation of
the transcription factor MEF2C, thereby adversely af-
fecting downstream effectors of neuronal survival and
adult neurogenesis [68,70]. Importantly, memantine, an
FDA-approved, uncompetitive NMDAR open-channel
blocker, at proper concentration, preferentially blocks
pathologically-stimulated eNMDARs over physiologically-
activated synaptic NMDARs (sNMDARs) [71]. Indeed,
application of memantine, and to a greater degree its im-
proved derivative NitroMemantine [72], has been shown
to mitigate Aβ-induced synaptic dysfunction and cognitive
deficits [63,73]. Taken together, these studies depict an al-
ternative mechanism underlying Aβ-induced synaptic dys-
function based on glutamate-mediated hyperexcitability
and synaptic excitotoxicity: Aβ-induced accumulation of
excessive glutamate in the extrasynaptic space can occur
through disruption of the glutamate uptake system or by
triggering astrocytic glutamate release, which in turn aber-
rantly activates eNMDARs and induces synaptic dysfunc-
tion (Figure 1).
NMDAR and AMPAR function at postsynaptic sites
are influenced by interaction with PSD-95, an important
postsynaptic scaffolding protein that plays a critical role
in protein assembly, synaptic development and neural
plasticity [74,75]. Under pathological conditions how-
ever, synaptic PSD-95 levels are decreased in AD post-
mortem brains, and the degree of reduction correlates
with both the level of Aβ oligomers and the severity of
dementia [21,76-78]. Similarly, PSD-95 is also reduced
in AD transgenic mouse neurons or neurons exposed to
Aβ oligomers, concomitant with dendritic spine loss and
surface AMPAR removal [51,52,79]. These results sug-
gest that synaptic disruption of PSD-95 may play a role
in the pathogenesis of AD. Consistent with this idea, it
has been shown by co-immunoprecipitation that Aβ in-
teracts with PSD-95 and is co-localized with PSD-95
specifically at excitatory synapses in human postmortem
AD brain as well as in cultured murine neurons exposed
to Aβ oligomers [21,80]. Therefore, it is possible that
Aβ may interact with PSD-95 directly to cause synaptic
damage under pathological conditions. Interestingly, over-
expression of α1-takusan, a PSD-95-binding and synaptic-
stabilizing protein [81], decreases Aβ-induced synaptic
damage, protecting from dendritic spine loss, de-
creased synaptic expression of PSD-95, and downregu-
lated AMPAR-mediated synaptic currents in cultured
neurons [82]. Further evidence has shown that increased
PSD-95 expression in hippocampus after treatment withthe Hsp90 inhibitor 17-AAG can improve cognitive func-
tion in an animal model of AD, apparently via synaptic en-
hancement [83]. Therefore, molecules that modulate the
integrity of PSD-95 and improve synaptic functions may
have therapeutic potential for reducing Aβ-induced synap-
tic injury and cognitive impairment in AD.
A number of other synaptic proteins have been pro-
posed to be putative receptors for Aβ oligomers, and
play important roles in oligomeric Aβ-induced synaptic
dysfunction and cognitive impairment. For example, sol-
uble Aβ oligomers can bind with nanomolar affinity to
PrPC, and PrP knockout or anti-PrP antibodies can rescue
oligomeric Aβ-induced synaptic dysfunction and spatial
memory. These results suggest that prion proteins play an
important role in AD pathogenesis [20]. The α7nAChR
modulates calcium homeostasis and release of the neuro-
transmitter glutamate, two important parameters involved
in learning and memory. Endogenous Aβ species have
been reported to bind to α7nAChRs with nanomolar affin-
ity in co-immunoprecipitation experiments on human AD
postmortem brain extracts [15]. This interaction conse-
quently triggers α7nAChR-dependent NMDAR endocyto-
sis leading to synaptic and cognitive dysfunction [15,56].
The ephrin family of receptor tyrosine kinases has also
been found to be a potential receptor that interacts with
Aβ oligomers under pathological conditions. It has been
shown that Aβ oligomer binding to EphB2 induces its deg-
radation, leading to impairments in NMDAR-mediated
synaptic activity and cognitive function [23]. Conversely,
EphB2 overexpression reverses deficits in NMDAR-
dependent LTP and cognitive impairments in AD Tg mice
[23]. Recently, ephrin A4 (EphA4), another ephrin receptor
family member, was also identified as a putative Aβ recep-
tor [24,25]. In contrast to EphB2 degradation, interaction
with Aβ activates EphA4, leading to suppression of LTP
and spine loss in AD transgenic mice. Application of either
EphA4 shRNA or EphA4 inhibitors/antagonists has been
reported to rescue these deficits, suggesting that EphA4 ac-
tivation plays a critical role in Aβ-induced synaptic dys-
function [24,25].
Alternative pathways contribute to Aβ-induced synaptic
and neuronal loss in AD
Aβ-induced synaptic dysfunction can also be mediated
by molecules and their downstream pathways that are
not directly associated with NMDA receptor-mediated
activities. It has been shown that Aβ can bind to the
low-affinity p75 neurotrophin receptor (p75NTR) and
activate its death domain to induce apoptosis [19].
Moreover, surface expression level of p75 is upregulated in
SH-SY5Y neuroblastoma cells after exposure to Aβ oligo-
mers and in hippocampal neurons in AD transgenic mice
[84]. Consistent with these animal studies, the level of
membrane-associated p75 in hippocampus was significantly
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matched controls [85]. Interestingly, APP cleavage is differ-
entially regulated by the neurotrophin high-affinity receptor
TrkA and the low-affinity receptor p75NTR; p75NTR pro-
motes whereas TrkA decreases APP β-cleavage [86]. There-
fore, aberrantly upregulated p75NTR together with TrkA
downregulation in aged brains results in increased Aβ gen-
eration [87]. In addition, p75NTR may also enhance Aβ pro-
duction via its ability to stabilize BACE1 or β-secretase
through the activation of sphingomyelinase and consequent
ceramide production [87,88].
In addition to neurotrophin receptors, insulin and
insulin-like growth factor receptors and their cognate sig-
naling pathways play a critical role in synaptic plasticity
and cognitive function by affecting both excitatory and in-
hibitory synaptic activity [89,90]. Growing evidence sug-
gests that AD may represent a metabolic disease of the
brain associated with brain insulin and insulin-like growth
factor-I (IGF-I) resistance and deficiency. Impaired insulin
signaling may contribute to dysregulation of downstream
pro-survival pathways, including decreased signaling me-
diated by PI3K, Akt, and Wnt/β-catenin; moreover, dis-
rupted insulin-related signaling may enhance pathogenic
pathways such as GSK-3β to trigger tau hyperphosphory-
lation [91,92]. Therefore, disrupted components of brain
insulin signaling pathways may represent potential thera-
peutic targets in AD [91,92]. It has been suggested that
both extracellular and intracellular Aβ oligomers contrib-
ute to neuronal dysfunction. Intracellular Aβ inhibits insu-
lin receptor signaling by interfering with the interaction
between phosphoinositide-dependent kinase (PDK) and
Akt, thus inhibiting Akt activation and abolishing insulin-
mediated neuroprotection [93]. Extracellular Aβ oligomers
or ADDLs bound to synaptic sites can induce removal of
surface insulin receptors and contribute to synaptic loss,
which can be rescued by insulin treatment [94]. Encour-
aging results obtained from intranasal insulin therapy in
aged adults [95] as well as in AD and MCI patients [96]
support the idea that insulin signaling is disrupted during
normal aging and in clinical cases of dementia.
Furthermore, Wnt family members promote synaptic
formation and regulate synaptic function by binding to
receptors of the Frizzled (Fz) and low-density lipoprotein-
related protein (LRP) families on the cell surface to acti-
vate either β-catenin-dependent canonical signaling (Wnt/
β-catenin) or β-catenin-independent non-canonical signal-
ing pathways; the latter pathways include the Wnt/PCP
and Wnt/Ca2+ cascades [97]. Multiple Wnt signaling com-
ponents are dysregulated in AD and such impairments are
likely to contribute to synaptic dysfunction and cognitive
decline in AD. Wnt co-receptor LRP6 variants suppress
Wnt signaling activity and are associated with late-onset
AD [98]. An endogenous Wnt inhibitor, Dickkopf-1
(Dkk1), which disrupts Wnt-induced Fz/LRP complexformation [99], is increased in human postmortem AD
brains [100] and mouse model AD brains [101], where
Dkk1 has been found to co-localize with active GSK-3 and
phospho-tau. Additional studies suggest that Dkk1 levels
increase after Aβ oligomer exposure [102]. Dkk1 upregula-
tion appears to be required for Aβ-induced synaptic loss
since synaptic damage as well as tau phosphorylation are
abolished by either Dkk1 knockdown [100] or Dkk1 block-
ing antibodies [102]. Interestingly, it has been shown that
Aβ may directly interact with Fz receptors of Wnt ligands
[103] although the significance of this interaction remains
to be determined. Taken together, these studies suggest that
dysregulated Wnt signaling contributes to Aβ-induced syn-
aptic loss in AD, which raises the possibility that Wnt sig-
naling components may represent potential therapeutic
targets in AD.
Aberrant neuronal network activity and seizures in AD
Epileptic seizures were once considered to be rare or an
epiphenomenon in AD. However, accumulating evidence
suggests that increased seizure activity may be the con-
sequence of a disrupted neuronal network, contributing
to cognitive decline and the onset of dementia [104]. It
has been estimated that 10 to 22% of AD patients ex-
perience at least one episode of an unprovoked seizure
[105]. However, it is likely that these numbers are under-
estimates for the following reasons: (1) AD patients with
dementia may not recall having seizures if they were un-
witnessed, and (2) some types of seizure activity, includ-
ing complex partial seizures, manifest symptoms such as
confusion or delirium, which are similar to those nor-
mally seen in AD patients, and therefore may go un-
detected. Prior observational studies have shown that
the occurrence of a first unprovoked seizure in patients
55 years or older is significantly greater in AD and other
dementias compared to the general population [106].
The increased incidence can be as high as 87-fold in AD
patients with early-onset FAD [107]. Consistent with this
result, a more recent study found that FAD mutations in
APP, PSEN1, and PSEN2 are all associated with higher
risk for a first unprovoked seizure [108]. These results
suggest a tight association between epileptic seizures
and genetic mutations that cause aberrant expression of
Aβ oligomers and induce early-onset AD.
Mechanistic insight into this abnormal excitatory
phenomenon was obtained in studies using AD transgenic
mice expressing human mutant APP and presenilin genes.
Several early studies showed that AD transgenic mice ex-
pressing human Aβ fragments [109] or APP mutations
[110,111] exhibit increased spontaneous seizure activity,
although these unprovoked seizure events are rare and
often ignored. Detection of subtle seizure phenotypes (or
nonconvulsive seizures) and aberrant neuronal network
activities have been made possible through the use of
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transgenic mice expressing FAD mutations [112-114].
Acute application of levetiracetam (LEV or Keppra®), an
antiepileptic drug, can effectively suppress abnormal EEG
spike activity, and chronic treatment with LEV can even
reverse AD-like phenotypes including synaptic dysfunc-
tion, hippocampal remodeling, and learning and memory
deficits in human APP transgenic mice [115]. Therefore,
antiepileptic drugs, such as LEV, that suppress the aber-
rant electrical activity that contributes to seizures may
provide an alternative approach to the treatment of AD.
Aβ-induced tau hyperphosphorylation and its role in
synaptic loss
The presence of hyperphosphorylated tau-enriched neuro-
fibrillary tangles is one of the classical pathological hall-
marks of AD. Tau is a microtubule-associated protein
(MAP) that was originally identified as an important
protein for microtubule (MT) assembly [116] and for
stabilization of the MT network [117]. Under pathological
conditions, tau becomes hyperphosphorylated and disas-
sociated from microtubules, subsequently forming soluble
aggregates, insoluble filaments, and eventually neurofibril-
lary tangles (NFTs) in affected brain regions. This path-
ology occurs not only in AD but also in several other
neurological disorders, which are collectively termed tauo-
pathies [118,119]. Phosphorylated tau (p-tau) colocalizes
with Aβ in synaptic terminals from both postmortem AD
brain [120,121] and transgenic mouse AD brain [122].
These prior studies have shown that expression of p-tau in
synaptic terminals correlates with Aβ levels, and increased
p-tau expression also correlates with a reduction in total
synapse number. A causal association between oligomeric
Aβ exposure and p-tau formation has been demonstrated
in several studies. For example, Talantova et al. [63] re-
ported that oligomeric Aβ caused astrocytic glutamate re-
lease, which in turn activated extrasynaptic NMDARs,
resulting in increased p-tau levels. Additional studies have
shown that Aβ-induced synaptic loss is tau-dependent
since tau deletion or reduction can rescue Aβ-induced
synaptic loss and cognitive impairment in AD transgenic
mice [123-126]. Moreover, a recent study characterized in-
teractions between oligomeric Aβ and p-tau in both hu-
man and animal AD brains by co-immunoprecipitation
and immunohistology, and this interaction progressively
increased with disease progression [127]. It is thus possible
that pathological interactions between oligomeric Aβ and
p-tau are important intermediate steps in Aβ-induced syn-
aptic loss and neuronal damage. Although previously
known as an axonal protein, tau is also expressed in den-
drites and in the postsynaptic density, albeit at much
lower levels [124]. Depletion of dendritic or postsynaptic
tau prevents abnormal postsynaptic targeting of the tyro-
sine kinase Fyn and rescues impaired learning andmemory function in AD transgenic mice, suggesting a vital
role of dendritic and postsynaptic tau in Aβ-induced syn-
aptic loss [124]. In cultured neurons, Aβ-induced tau
hyperphosphorylation and dendritic disruption can be at-
tenuated by anti-Aβ antibodies or tau reduction using
RNAi-targeting strategies [128-130]. Therefore, it is
possible that Aβ-induced tau hyperphosphorylation is
an important intermediate event that leads to synaptic
dysfunction. Indeed, only pseudohyperphosphorylated
tau, which mimics hyperphosphorylated tau, but not
phosphorylation-deficient tau, which mimics regular
tau, is mislocalized and accumulated in dendritic spines
[131]. Consequently, hyperphosphorylated tau that is
mislocalized to dendritic spines has been reported to in-
duce synaptic dysfunction by impairing AMPAR surface
expression and synaptic transmission [131]. Consistent
with this finding, tau deletion or inhibition of tau hyper-
phosphorylation using a glycogen synthase kinase 3β
(GSK-3β) inhibitor can prevent Aβ-induced impairment
of LTP [132]. GSK-3β-mediated tau phosphorylation
and Aβ production can also be reduced by RPS23R1
protein via activation of the adenylate cyclase/cAMP/
PKA pathway. In turn, this pathway leads to synaptic
enhancement and improved AD pathology [133]. Tau-
dependent synaptic dysfunction may also involve the
tyrosine kinase Fyn [124]. Pseudohyperphosphorylated
tau binds Fyn more tightly than wild-type tau, thus in-
creasing Fyn activity and leading to synaptic damage
[134]. Intriguingly, a study using human AD induced
pluripotent stem cell (iPSC)-derived neurons has suggested
that increased tau phosphorylation at Thr231 is mediated
by β-secretase activity [135]. This finding raises the possi-
bility that Aβ-induced tau pathology and synaptic damage
can be mediated by an alternative, non-Aβ-mediated path-
way. Thus, future in-depth studies will determine the role
of dendritic/postsynaptic tau and its hyperphosphorylation
in Aβ-induced synaptic loss.
Aβ-induced mitochondrial dysfunction and synaptic loss
in AD
Under physiological conditions, mitochondria provide
much of the energy that is required to maintain normal
synaptic activity and plasticity [136]. However, under
pathological conditions, mitochondrial impairment has
been suggested to be an important early event contributing
to synaptic loss and neurodegeneration in AD [137-139].
In human postmortem brains, Aβ has been reported to
accumulate aberrantly in mitochondria with abnormal
morphology, suggesting that Aβ may influence mitochon-
drial morphogenesis [140-143]. Wild-type neurons exposed
in vitro to oligomeric Aβ or AD transgenic neurons in vivo
exhibit excessive mitochondrial fission (mitochondrial frag-
mentation), a sign of impairment in mitochondrial dynam-
ics, further implicating Aβ in mitochondrial dysregulation
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concentrations can trigger mitochondrial impairment,
which in turn leads to bioenergetics compromise, synaptic
starvation and damage in AD. Consistent with this hypoth-
esis, mitochondrial impairment caused by oligomeric Aβ
or toxic factors generated downstream of Aβ, such as
RNS/NO, occurs prior to synaptic and neurite injury [148]
and precedes AD pathology [149]. It has been suggested
that abnormal interactions between Aβ and the mitochon-
drial fission protein dynamin-related protein 1 (Drp1) play
an important role in mitochondrial dysfunction and synap-
tic damage in AD [150]. Additional evidence suggests that
Aβ-induced mitochondrial impairment is likely mediated
by abnormal interaction between oligomeric Aβ and mito-
chondrial matrix protein ABAD [151] or cyclophilin D
(CypD) [152]. It has also been suggested that appopto-
sin, a glycine/5-amino-levulinic acid transporter medi-
ating heme synthesis in mitochondria, is involved in
Aβ-induced neurodegeneration by inducing ROS re-
lease and resultant apoptosis under pathological condi-
tions; these pathogenic processes can be prevented by
appoptosin downregulation [133].
Synaptic mitochondria, or mitochondria residing in
synapses, are usually older, and thus much more vulnerable
to persistent insults such as Aβ compared to nonsynapticFigure 2 Mitochondrial impairment and synaptic dysfunction in AD. (
affect mitochondrial fission proteins such as Drp1 and mitochondrial matrix
Aβ-induced mitochondrial fragmentation with consequent bioenergetics fa
vulnerable to pathological toxins than non-synaptic mitochondria. Aβ is als
non-synaptic mitochondria, thus enhancing damage on synaptic mitochonmitochondria. Aβ species reportedly also accumulate at
much higher levels in synaptic mitochondria compared to
nonsynaptic mitochondria [153,154]. Accordingly, synaptic
mitochondria show greater susceptibility to damage com-
pared to nonsynaptic mitochondria in AD transgenic mice
[153,154]. Mitochondrial function such as respiratory rate,
ROS production, membrane potential, and cytochrome c
oxidase activity are compromised more severely in synaptic
mitochondria than in nonsynaptic mitochondria [153,154].
The degree of mitochondrial impairment is also region-
specific. Greater damage is found in areas related to
learning and memory such as the hippocampus and cor-
tex, while only moderate damage is found in other brain
regions [154].
Tau pathology strongly correlates with mitochondrial
impairment [125,130,155-158], suggesting that tau may
play a role in Aβ-induced mitochondrial dysfunction. It
has been shown using immunoprecipitation and im-
munofluorescence that hyperphosphorylated tau abnor-
mally interacts and colocalizes with the mitochondrial
fission protein Drp1 in postmortem AD brains [158]. In
the same brain specimens, elevated levels of Drp1 and
mitochondrial fragmentation have also been identified
[150]. These studies suggest that hyperphosphorylated tau
is associated with Aβ-induced mitochondrial dysfunction,A) Under pathological conditions, Aβ oligomers directly or indirectly
proteins, including ABAD and CypD. Such interactions may mediate
ilure and resulting synaptic loss. (B) Synaptic mitochondria are more
o more likely accumulated in synaptic mitochondria than in
dria.
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neurons. Consistent with this notion, Aβ application in
cultured neurons results in elevated expression of mito-
chondrial fission proteins Drp1 and Fis1 and reduced
expression of fusion proteins Mfn1, Mfn2, and Opa1,
consistent with mitochondrial fragmentation phenotypes
observed in AD [146]. Additional recent evidence also sup-
ports a role for hyperphosphorylated tau in mitochondrial
impairment. For example, overexpression of the postsyn-
aptic protein α1-takusan inhibits Aβ-induced tau hyper-
phosphorylation and prevents Aβ-induced mitochondrial
fragmentation in cultured neurons [82].
Moreover, pathological redox reactions of mitochondrial
proteins triggered by oligomeric Aβ, in part mediated by
aberrant eNMDAR stimulation as discussed above, have
been described. These reactions include S-nitrosylation of
Drp1 (to form SNO-Drp1), resulting in excessive mito-
chondrial fission with consequent bioenergetic comprom-
ise and hence synaptic damage [64]. Interestingly, Cdk5
has been shown to act as a transnitrosylase, transferring
NO from Cdk5 to Drp1 (as opposed to the classical role
of Cdk5 as a kinase). Transnitrosylation hyperactivates
Drp1 under these disease conditions, and, importantly, S-
nitrosylation of Cdk5 is triggered by oligomeric Aβ peptide
[67]. Thus, the initial nitrosylation of Cdk5 may represent
in inciting event in mitochondrial fragmentation, with
resulting bioenergetic failure and synaptic loss. Figure 2
summarizes our current understanding of Aβ-induced
mitochondrial impairment as discussed above.
Conclusions
Accumulating evidence suggests that oligomeric Aβ plays a
central role in synaptic dysfunction and cognitive decline in
AD. Studies using animal models have revealed that Aβ-
induced synaptic dysfunction involves multiple pathological
events and various integral signaling systems, including
glutamate receptors and their downstream pathways, ab-
normal elevation of extrasynaptic glutamate levels and
subsequent eNMDAR-mediated excitotoxicity, tau hyper-
phosphorylation, and impaired mitochondria. However,
the relevance of these studies to AD in human remains de-
batable. Furthermore, the detailed molecular mechanisms
underlying these events are still not fully understood. Sev-
eral fundamental questions remain, such as the role of tau
phosphorylation in Aβ-induced synaptic dysfunction, the
physiological relevance of Aβ-binding partners or recep-
tors in neuronal degeneration, and even the direct role of
Aβ itself in AD. Since a large variety proteins and distinct-
ive pathways may be involved in the pathogenesis of AD,
there may be no definitive treatment that can ubiquitously
treat all AD patients. Indeed, the complexity of AD is ex-
emplified by a diverse set of genetic mutations associated
with AD. If this holds true, personalized drug candidates
may need to be developed to cater to various geneticprofiles, severity in cognitive decline, and other envir-
onmental factors. These challenges remain daunting.
However, development of new technologies to treat dys-
regulated molecular pathways downstream of Aβ and
phospho-tau may enable us to utilize our emerging
knowledge of these pathways in order to develop novel
strategies in the treatment and prevention of AD.
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